Second Phase Of Takeda’s Globalization Plan Calls For Partial Integration Of Millennium
This article was originally published in PharmAsia News
Executive Summary
The next phase of Takeda’s globalization strategy emphasizes organizational house cleaning. Millennium, which had operated as a standalone oncology outpost, will be partially integrated into Takeda R&D but the commitment to oncology in terms of resources and investment remains firm.
You may also be interested in...
Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back
Mortality for this deadly disease has been pushed back due to therapeutic innovations. But to make further strides, new mechanisms of action and combination approaches will need to come further into play. These advances and the eventual genericization of Velcade are likely to make the regulatory and payer environment increasingly complicated.
Astellas/Medivation Strengthen Case For Xtandi In Advance Of Second Filing
New PSA data from the AFFFIRM trial in post-chemo patients indicate prostate cancer drug Xtandi works equally well regardless how advanced the disease, a meaningful finding for heavily pretreated patients like those in the trial. Interim rPFS data from a chemo-naïve study will be available in the second half of 2013, but a supplemental filing most certainly will wait for overall survival results.
Affymax’s Omontys Recalled After Deaths; Uncertain Future Ahead For Company
Affymax and its partner Takeda recalled all of their ESA product after rare but unexplained patient fatalities, leaving both the product’s and the company’s future in limbo. The safety concerns may fuel fears about the unknowns of biologic production.